Source: Υπουργείο Υγείας (CY) Revision Year: 2022 Publisher: Delorbis Pharmaceuticals Ltd., 17 Athinon Street, Ergates Industrial Area, 2643 Ergates, P.O. Box 28629, 2081 Lefkosia, Cyprus, European Union
Saderon 2.5 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablets. Yellow, round, biconvex, film-coated tablets, debossed with '‘L9OO’‘ on one side and ’‘2.5’' on the other side. |
Each film-coated tablet contains 2.5 mg letrozole.
Excipient(s) with known effect: each film-coated tablet contains 61.5 mg of lactose monohydrate.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Letrozole |
Letrozole is a non-steroidal aromatase inhibitor. It inhibits the aromatase enzyme by competitively binding to the haem of the aromatase cytochrome P450, resulting in a reduction of oestrogen biosynthesis in all tissues where present. |
| List of Excipients |
|---|
|
Core tablet: Lactose monohydrate Coating: Hypromellose (HPMC) (E464) |
Saderon film-coated tablets are supplied in PVC/Alu blister packs of 30 tablets.
Delorbis Pharmaceuticals Ltd., 17 Athinon Street, Ergates Industrial Area, 2643 Ergates, P.O. Box 28629, 2081 Lefkosia, Cyprus, European Union
M.L.: 022803
25/05/2018
| Drug | Countries | |
|---|---|---|
| SADERON | Cyprus |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
